C12N 2795/10022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 78 US grants and 95 published applications in this corpus.
Search patents in C12N- Granted patents
- 78
- Published applications
- 95
- Assignees
- 88
- Inventors
- 230
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 3 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 4 | 0 |
| 1999 | 3 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 1 |
| 2002 | 5 | 2 |
| 2003 | 0 | 5 |
| 2004 | 5 | 6 |
| 2005 | 1 | 7 |
| 2006 | 2 | 3 |
| 2007 | 2 | 7 |
| 2008 | 4 | 0 |
| 2009 | 0 | 2 |
| 2010 | 4 | 5 |
| 2011 | 1 | 2 |
| 2012 | 3 | 4 |
| 2013 | 6 | 0 |
| 2014 | 1 | 3 |
| 2015 | 1 | 1 |
| 2016 | 5 | 4 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 5 |
| 2021 | 2 | 4 |
| 2022 | 5 | 6 |
| 2023 | 1 | 9 |
| 2024 | 3 | 5 |
| 2025 | 2 | 11 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Production and functionalization of nanoparticles derived from phage T5 and therapeutic uses13 Jan 2026US 12,521,432 B2Centre National de la Recherche Scientifique (CNRS)
- Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae19 Aug 2025US 12,390,512 B2Shanghai Reinovax Biologics Co., Ltd
- Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)13 May 2025US 12,296,002 B2Dynavax Technologies Corporation
- Protease activity profiling via programmable phage display of comprehensive proteome-scale peptide libraries17 Sep 2024US 12,091,776 B2The John Hopkins University
- Bacteriophage-derived nanopore sensors14 May 2024US 11,980,849 B2Ohio State Innovation Foundation
- Bacteria-targeting capsid particle, treatment composition, disinfectant, food, bacteria elimination method, bactericidal method, corrosion prevention method, animal treatment method, gene introduction method, bacteria function addition method, method for producing bacteria-targeting capsid particle, and method for producing nucleic acid for bacteria-targeting capsid particle25 Dec 2025US 2025/0387442 A1Jichi Medical University
- Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof13 Nov 2025US 2025/0345378 A1Locus Biosciences, Inc.
- Bacteriophage7 Aug 2025US 2025/0249085 A1Glaxosmithkline Biologicals SA
- Synthetic virus and provision thereof19 Jun 2025US 2025/0197816 A1Technische Universität München
- Anti-b7-h3 compounds and methods of use5 Jun 2025US 2025/0179186 A1Regents of the University of Minnesota
Most cited
By later US patents
- Recombinant mycobacterial vaccine72US 5,504,005 AAlbert Einstein College of Medicine of Yeshiva University · 1996
- Receptor-mediated gene delivery using bacteriophage vectors63US 6,054,312 ASelective Genetics, Inc. · 2000
- Phagemid for antibody screening59US 5,849,500 ADeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts · 1998
- Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis51US 5,439,808 ANorth American Vaccine, Inc. · 1995
- Methods of selecting internalizing antibodies47US 6,794,128 B2The Regents of the University of California · 2004